Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Patients in the fourth dosing cohort will receive ONCT-534, the company’s dual-action androgen receptor inhibitor (DAARI), at a dose of 300 mg taken orally each day.
- Patients in the fourth dosing cohort will receive ONCT-534, the company’s dual-action androgen receptor inhibitor (DAARI), at a dose of 300 mg taken orally each day.
- “Reaching the 300 mg dose level represents a significant milestone for our ONCT-534 program.
- “We continue to see strong demand from investigators and patients to participate in the study and expect to continue enrolling at a brisk pace.
- We look forward to announcing initial efficacy and safety data from the study, which we expect will be at the end of this quarter.”